00:47 , Jul 27, 2018 |  BC Innovations  |  Product R&D

Syncona’s sister act

With the final pieces of its gene therapy portfolio in place, Syncona Investment Management Ltd. thinks its five “sister companies” are poised to capitalize on recent regulatory and technological advances in gene therapy, and push...
01:24 , Jan 18, 2018 |  BC Extra  |  Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in Nature brings into question the safety and efficacy of activating the transmembrane protein 173 (STING; TMEM173) pathway -- which triggers immune responses in the presence of cytosolic DNA -- in cancers...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
00:55 , Nov 8, 2016 |  BC Extra  |  Financial News

Syncona pooling resources with U.K. cancer investors

The Syncona investment arm of the Wellcome Trust and cancer-focused investment firm BACIT Ltd. (LSE:BACT) proposed a deal in which they would combine to form a publicly traded life sciences investment company with about L1...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Financial News

Achilles Therapeutics completes venture financing

Achilles Therapeutics Ltd., London, U.K.   Business: Cancer   Date completed: 2016-10-05   Type: Venture financing   Raised: L13.2 million ($17 million)   Investors: Syncona Partners LLP; CRT Pioneer Fund; UCL Technology Fund   ...
07:00 , Oct 4, 2016 |  BC Extra  |  Financial News

Cancer newco Achilles debuts with L14.2M

Cancer company Achilles Therapeutics Ltd. (London, U.K.) raised L14.2 million ($18.3 million) in a venture round led by Syncona. The CRT Pioneer Fund of Cancer Research Technology and the UCL Technology Fund also participated. Achilles...